Development of a clinical study manuscript for fast-track publication by The Lancet
Two leading multinational biotechnology companies.
In collaboration with an extensive network of clinician researchers, our clients had obtained highly encouraging data in a phase II randomised controlled trial. The drug under investigation belonged to a relatively new class of compounds and the study had been conducted using rigorous methodology. Given the strength of the data, our clients wished to publish their study promptly in a high impact journal. The Lancet was selected due to its reputation (impact factor 45) as well as its broad scope, which would allow the findings to reach a wide range of healthcare professionals and researchers.
Working closely with the authors, Aspire Scientific led the project from initial manuscript outline to acceptance for fast-track publication by The Lancet only a few months later. The Aspire Scientific team provided editorial support including development of manuscript drafts in consultation with the authors, collating author comments, and preparing tables, figures and references. All work was completed in accordance with Good Publication Practice and the CONSORT guidelines. Aspire Scientific also assisted the authors with submission of their manuscript, including collating their responses to peer reviewers under the tight deadlines imposed by fast-track status. Our clients were delighted with the acceptance of their manuscript.
For further information about how Aspire Scientific can help you with the development of your clinical manuscript(s), please contact Ryan Woodrow